Halozyme Therapeutics, Inc.HALONASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +29.55% | +35.22% | +40.79% | +22.12% | +51.60% |
| Gross Profit Growth | +44.00% | +44.51% | +60.57% | +24.25% | +36.60% |
| EBITDA Growth | +59.86% | +45.84% | +67.03% | +49.78% | +38.35% |
| Operating Income Growth | +73.70% | +48.14% | +72.68% | +33.53% | +44.95% |
| Net Income Growth | +60.46% | +53.72% | +77.12% | +27.89% | -203.34% |
| EPS Growth | +63.64% | +57.38% | +86.30% | +37.96% | -211.11% |
| EPS Diluted Growth | +63.08% | +55.00% | +84.72% | +36.19% | -213.21% |
| Weighted Average Shares Growth | -2.05% | -2.94% | -4.54% | -7.59% | -6.91% |
| Weighted Average Shares Diluted Growth | -1.23% | -1.74% | -3.92% | -6.00% | -9.08% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +74.36% | +19.16% | +78.71% | +54.80% | +22.73% |
| Free Cash Flow Growth | +75.84% | +21.76% | +84.45% | +54.20% | +24.05% |
| Receivables Growth | +31.70% | +55.50% | +47.46% | +21.10% | +43.06% |
| Inventory Growth | +11.17% | -2.18% | +13.93% | +41.38% | +24.40% |
| Asset Growth | +19.05% | +19.28% | +4.29% | +4.87% | +22.38% |
| Book Value per Share Growth | +343.21% | +179.43% | +20.44% | +20.46% | -85.59% |
| Debt Growth | +0.44% | +0.44% | +0.44% | +0.44% | -100.00% |
| R&D Expense Growth | -4.19% | -22.56% | -16.61% | -6.54% | +56.04% |
| SG&A Expenses Growth | +12.34% | +20.57% | +16.53% | +11.75% | +49.89% |